A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary Care

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue SUPPL. 1, 2011, Pages

  Cheever, Laura W ^a   Kresina, Thomas F ^b   Cajina, Adan ^a   Lubran, Robert ^b  

^a HEALTH RESOURCES AND SERVICES ADMINISTRATION   (United States)

^b SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION   (United States)

Author keywords

buprenorphine; HIV AIDS; primary care

Indexed keywords

BUPRENORPHINE; METHADONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DRUG ABUSE; DRUG DOSE INCREASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENTAL HEALTH SERVICE; OPIATE ADDICTION; PATIENT ATTITUDE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL;

BUPRENORPHINE; HIV INFECTIONS; HUMANS; INTERDISCIPLINARY COMMUNICATION; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; UNITED STATES;

EID: 79951781216     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318209740f     Document Type: Article

References (23)

1. Cook JA, Grey DD, Burke-Miller JK, et al. Illicit drug use, depression and their association with highly active antiretr (Pubitemid 46602873)
2. UNAIDS/WHO. Report on the global HIV/AIDS epidemic 2010. 2010. Geneva, UNAIDS. Available at: http://www.unaids.org/globalreport. Accessed January 3, 2011.
3. Batkis MF, Treisman GJ, Angelino AF. Integrated opioid disorder and HIV treatment: rationale, clinical guidelines for addiction treatment, and review of interactions of antiretroviral agents and opioid agoinst theapies. AIDS Patient Care STD. 2010;24:15-22.
4. Mendelson J, Flower K, Pletcher MJ, et al. Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine. Exp Clin Psychopharmacol. 2008;16:435-441.
5. Basu S, Bruce RD, Barry DT, et al. Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence. J Subst Abuse Treat. 2007;32:399-409. (Pubitemid 46661125)
6. Magura S, Lee SJ, Salsitz EA, et al. Outcomes of buprenorphine maintenance in office-based practice. J Addict Dis. 2007;26:13-23. (Pubitemid 47413818)
7. Moore BA, Fiellin DA, Barry DT, et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med. 2007;22:527-530. (Pubitemid 46941212)
8. Soeffing JM, Martin LD, Fingerhood MI, et al. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat. 2009;37:426-430.
9. Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2004;CD002207.
10. Friedman SR, Tempalski B, Brady JE, et al. Predictors of the degree of drug treatment coverage for injection drug users in 94 metropolitan areas in the United States of America. Int J Drug Policy. 2007;18:475-485. (Pubitemid 350186097)
11. Friedman SR, Tempalski B, Cooper H, et al. Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. J Urban Health. 2004;81:377-400. (Pubitemid 39128276)
12. Substance Abuse and Mental Health Services Administration (SAMH-SA). National Survey of Substance Abuse Treatment Services (N-SSATS). Available at: http://oas.samhsa.gov/dasis.htm#nssats2. 2010. Accessed January 3, 2011.
13. Centers for Disease Control and Prevention (CDC). HIV/AIDS in the United States Fact Sheet. Available at: www.cdc.gov/hiv/resources/ factsheets/us.htm. 8-21-2010. Divisions of HIV/AIDS Prevention National Center for HIV/ADIS, Viral Hepatitis, STD and TB prevention. Accessed January 3, 2011.
14. Centers for Disease Control and Prevention (CDC). Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Soc. MMWR Recomm Rep. 2003; 52:1-24.
15. Katz MH, Cunningham WE, Mor V, et al. Prevalence and predictors of unmet need for supportive services among HIV-infected persons: impact of case management. Med Care. 2000;38:58-69.
16. Koob GF. Neuroadaptive mechanisms of addiction: studies on the extended amygdale. Eur Neuropsychopharmacol. 2003;13:442-452. (Pubitemid 37433964)
17. Substance Abuse and Mental Health Services Administration (SAMHSA) Results from the 2008 National Survey on Drug Use and Health: National Findings. Table 5.2B-Substance Dependence or Abuse for Specific Substances in the Past year, by Age group: Percentages, 2007 and 2008. Available at: http://oas.samhsa.gov/NSDUH/2K8NSDUH/tabs/Sect5pe-Tabs1to56.htm#Tab5.1A. Accessed January 3, 2011.
18. Kresina TF, Bruce RD, Cance-Katz EF. Medication assisted treatment in the treatment of drug abuse and dependence in HIV/AIDS infected drug users. Curr HIV Res. 2009;7:354-364.
19. Compton WM, Thomas YF, Stinson FS, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64:566-576. (Pubitemid 46718289)
20. Basu S, Smith-Rohrberg D, Brice RD. Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis. 2006;42:716-721. (Pubitemid 43271389)
21. Hanson T, Alessi SM, Petry NM. Contingency management reduces drug-related human immunodeficiency virus risk behaviors in cocaine-abusing methadone patients. Addicition. 2008;103:1187-1197. (Pubitemid 351843401)
22. DATA 2000. Drug Abuse Treatment Act. Available at: http://buprenor-phine. samhsa.gov/./fulllaw.html. Accessed January 3, 2011.
23. Weiss L, Netherland J, Egan JE, et al; BHIVES Collaborative. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011; 56(Suppl 1):S7-S13.